Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics

Reata Pharmaceuticals, Inc. - (RETA): $172.36

0.04 (+0.02%)

POWR Rating

Component Grades








RETA Price/Volume Stats

Current price $172.36 52-week high $172.46
Prev. close $172.32 52-week low $21.83
Day low $172.32 Volume 1,988,500
Day high $172.46 Avg. volume 1,091,032
50-day MA $158.53 Dividend yield N/A
200-day MA $95.04 Market Cap 6.58B

RETA Stock Price Chart Interactive Chart >

Reata Pharmaceuticals, Inc. - (RETA) Company Bio

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.

RETA Latest News Stream

Event/Time News Detail
Loading, please wait...

RETA Latest Social Stream

Loading social stream, please wait...

View Full RETA Social Stream

Latest RETA News From Around the Web

Below are the latest news stories about REATA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Should You Add Reata Pharmaceuticals (RETA) to Your Portfolio?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […]

Yahoo | September 25, 2023

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen").

Yahoo | September 21, 2023

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near Future

Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would...

Yahoo | September 13, 2023

Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?

As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash. Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen. First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat Friedreich's ataxia.

Yahoo | September 9, 2023

Insider Sell: SVP, Chief Accounting Officer Bhaskar Anand Sells 406 Shares of Reata ...

On September 5, 2023, Bhaskar Anand, the SVP, Chief Accounting Officer of Reata Pharmaceuticals Inc (NASDAQ:RETA), sold 406 shares of the company.

Yahoo | September 8, 2023

Read More 'RETA' Stories Here

RETA Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 72.58%
3-year 93.10%
5-year 119.51%
2023 0.00%
2022 44.07%
2021 -78.67%
2020 -39.53%
2019 264.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!